COPD
AstraZeneca completes respiratory deal with Actavis
March 3, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast
AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …
Second late-stage COPD trial for GSK and Theravance
February 10, 2015Sales and Marketing COPD, FF/UMEC/VI, GSK, Theravance, fluticasone furoate, umeclidinium, vilanterol
GlaxoSmithKline and Theravance have begun a second Phase III trial of their investigational triple combination COPD drug as the former …
GSK double complaint ruled out by PMCPA
January 16, 2015Medical Communications, Sales and Marketing ABPI, COPD, GSK, PMCPA, Relvar, Seretide
Complaints questioning the promotion of two of GlaxoSmithKline’s chronic obstructive pulmonary disease (COPD) drugs have been ruled out by a …
Boehringer complaint ruled out by PMCPA
January 15, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, COPD, PMCPA, Striverdi, olodaterol
A complaint made by a pharmacist stating that the artwork image for Boehringer Ingelheim’s COPD drug Striverdi is misleading has …
Vectura and J&J shake on asthma/COPD deal
January 6, 2015Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura
British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …
Europe must prepare for COPD ‘timebomb’
November 19, 2014Sales and Marketing COPD, Europe, European COPD Coalition, Spiriva, asthma, chronic obstructive pulmonary disease
Health services in Europe are not making sufficient effort to cope with the escalating burden of chronic obstructive pulmonary disease …
Gamification: what’s in it for the pharma industry?
October 6, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AF, Boehringer, COPD, CRUK, Gamification, ROI, Syrum, digital
Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This …
Boehringer’s Striverdi gains FDA approval
August 1, 2014Sales and Marketing Advair, COPD, Pfizer, Spiriva, asthma, olodaterol
Boehringer Ingelheim’s new lung drug Striverdi has gained US approval for patients with chronic obstructive pulmonary disorder. Striverdi Respimat (olodaterol), …
AstraZeneca signs $240m asthma deal with UK biotech
June 12, 2014Sales and Marketing AZ, AstraZeneca, COPD, SNG001, Synairgen
UK-based Synairgen has signed a global licence agreement with fellow British native AstraZeneca for its experimental lung drug SNG001. The …
Europe poised for generic Symbicort
February 24, 2014Manufacturing and Production, Sales and Marketing AstraZeneca, CHMP, COPD, Symbicort, Teva, breo, generics
The CHMP has given Teva Pharmaceutical Industries a lift by recommending that its generic version of AstraZeneca’s lung drug Symbicort …
CHMP breathes new life into GSK, Teva and Novartis
February 24, 2014Research and Development, Sales and Marketing CHMP, COPD, EMA, GSK, Gilead, Teva, asthma, onoro
The CHMP has given its backing to a number of new treatments for respiratory diseases, which include two from London-based …
GSK/Theravance lung drug bags CHMP approval
February 21, 2014Sales and Marketing CHMP, COPD, GSK, Theravance, anoro
The CHMP has given its backing to GlaxoSmithKline and partner Theravance’s new chronic obstructive pulmonary disease medicine Anoro. The treatment …
GSK banks on bioelectronics with new fund
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bioelectronics, COPD, GSK, asthma, diabetes
GSK has established a $50 million venture capital fund to invest in the emerging field of bioelectronics. Described as one …
AstraZeneca to pay up to $1.2 billion for Pearl
June 10, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, pearl therapeutics
AstraZeneca is betting big on lung disease specialist Pearl Therapeutics as it looks to spend $1.2 billion to acquire the …
GSK submits UMEC monotherapy
April 29, 2013Sales and Marketing COPD, EMA, GSK, UMEC
GlaxoSmithKline has put its investigational once-daily medicine umeclidinium bromide (UMEC) up for scrutiny by European regulators for patients with chronic …
Latest content
Five Facts about cardiovascular disease
